The effect of ultra-dose of vitamin D3 on critical children

Evaluation of the effect of ultra-dose of vitamin D3 as 10000 IU/Kg on clinical and laboratory results of critical children admitted to PICU

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT20221129056657N1

Enrollment

138

Registered

2023-01-17

Start date

2019-04-21

Completion date

Unknown

Last updated

2023-02-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Vitamin D deficiency in critically ill children.

Interventions

Intervention 1: The usual dose of vitamin D3 is 2000 IU orally (gavage), once a day, for 7 days - manufactured by Zahrawi Pharmaceutical Company, Tabriz. Intervention 2: Ultra dose of vitamin D3 in th

Eligibility

Sex/Gender

All

Age

1 Months to 18 Years

Inclusion criteria

Inclusion criteria: Age of one month to 18 years Healthy children Critically ill children admitted to the PICU Healthy children

Exclusion criteria

Exclusion criteria: Chronic kidney disease and nephritic syndrome Severe parenchymal or obstructive liver disease Vitamin D-dependent rickets type B1 (VDDR-1B) and type A1 (VDDR-1A) Hereditary vitamin D resistant rickets (HVDRR) High-dose glucocorticoid treatment AIDS treated with antiretroviral drugs Patients treated with phenytoin, phenobarbital, carbamazepine, isoniazid, theophylline and high doses of glucocorticoid Lack of oral or enteral nutrition Patients with hypercalcemia, intestinal malabsorption such as celiac disease and IBD, exocrine pancreatic disorder such as cystic fibrosis History of bowel resection or bariatric surgery Suffering from a chronic disease or current severe disease (in outpatients)

Design outcomes

Primary

Measure	Time frame
C-reactive protein factor. Timepoint: on the first day of the study and the seventh day after the intervention. Method of measurement: Taking blood samples and laboratory kits.;Length of hospitalization in the intensive care unit. Timepoint: On the seventh day after the intervention. Method of measurement: Refer to the patient file.	—

Secondary

Measure	Time frame
Percentage of possible mortality. Timepoint: First day of study. Method of measurement: Completing the Prism form.;Duration of hospitalization. Timepoint: The seventh day after the start of the intervention. Method of measurement: Complete the checklist.;Duration of intubation. Timepoint: The seventh day after the start of the intervention. Method of measurement: Complete the checklist.;Vitamin D levels. Timepoint: The first day of the study and the seventh day after the start of the intervention. Method of measurement: Using the ELISA laboratory kit (Enzyme-linked immuno_sorbent assay).	—

Measure

Time frame

Percentage of possible mortality. Timepoint: First day of study. Method of measurement: Completing the Prism form.;Duration of hospitalization. Timepoint: The seventh day after the start of the intervention. Method of measurement: Complete the checklist.;Duration of intubation. Timepoint: The seventh day after the start of the intervention. Method of measurement: Complete the checklist.;Vitamin D levels. Timepoint: The first day of the study and the seventh day after the start of the intervention. Method of measurement: Using the ELISA laboratory kit (Enzyme-linked immuno_sorbent assay).

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactGholamreza Khademi

Mashhad University of Medical Sciences

khademigh@mums.ac.ir+98 51 3871 3801

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026